Emerging Therapies: Nucala (US) is a three-wave syndicated detailed expanded analysis that specifically tracks the introduction of Nucala, the first IL-5 inhibitor approved to treat eosinophilic asthma. This report series is based on primary research data collected at one month, six months, and one year post-commercial availability of Nucala. Along with awareness and sources of familiarity, the reports assess U.S. pulmonologists’ and allergists’ trial, adoption, and use of Nucala, including anticipated future trends. The report also provides information on product perception, satisfaction, obstacles to use, drivers of prescribing, patient types, displacement of competitors, GlaxoSmithKline’s promotional efforts, and benchmarking against previously launched immune biologic therapies. This module also includes an overview and pipeline analysis of emerging asthma therapies from early to late phase clinical development, as well as detailed profiles, expert insights, and commercial outlook for select therapies in late phase commercial development.

Table of contents

  • Asthma - Emerging Therapies - Nucala Launch Tracking (US) Wave 1
    • Key Findings
      • Aided Awareness of Nucala and Its Indication Is High;the Majority of Physicians Have Seen a Nucala
        • Physician Opinion
      • Who Is the Nucala Patient?
        • Who Is the Nucala Prescriber?
          • Trends and the Asthma Market
            • Trends Regarding the Uptake of Nucala: Anticipated Number of Nucala Patients
            • Nucala’s Place in the Asthma Market
            • Physician Opinion
        • Benchmarking Nucala Launch Success vs. Various Immune Biologic Analogues
          • Prescriber and Nonprescriber Profiles
            • Nucala: Differences Between Prescriber and Nonprescriber Profiles
          • Nucala Awareness and Perceptions
            • Unaided and Aided Awareness of Nucala
              • Asthma Treatments Available
              • Physician Opinion
              • Current Treatment . . . in Their Own Words
              • Physician Opinion
              • Changes Made to Asthma Treatment . . . in Their Own Words
              • Awareness of Nucala Among Pulmonologists and Allergists
              • Indications in Which Physicians Are Aware Nucala Is Approved
              • Patients for Which Physicians Are Aware Nucala Is Approved
            • Familiarity with Nucala
              • Familiarity with Nucala Among Pulmonologists and Allergists
              • Level of Familiarity
            • Sources of Familiarity with Nucala
              • Sources of Familiarity . . . in Their Own Words
            • Initial Reaction to and Interest in Nucala
              • Product Profile for Nucala
              • Initial Reactions to Nucala
              • Awareness of Nucala Profile
              • Physician Opinion
              • Awareness of Nucala Profile
              • Physician Opinion
              • Interest in Nucala
            • Impressions of Nucala
              • Perceived Uniqueness of Nucala
              • Unaided Advantages of Nucala
              • Unaided Disadvantages of Nucala
              • Advantages of Nucala . . . in Their Own Words
              • Disadvantages of Nucala . . . in Their Own Words
              • Risk-Benefit Profile Balance
            • Prescriber and Nonprescriber Profiles
              • Nucala: Differences Between Prescriber and Nonprescriber Profiles
          • Nucala Trial and Use
            • Willingness to Prescribe Nucala
              • Number of Patients Currently Receiving Nucala
                • Prescriber vs. Nonprescriber
                • Number of Patients Ever Prescribed
                • Initial Nucala Prescribing . . . in their Own Words
                • Nucala Patient Inquiries
                • Starting Patients Who Specifically Requested Nucala
                • Nucala Patient Inquiries
                • Starting Patients Who Specifically Requested Nucala
                • Patient Requests for Nucala . . . in Their Own Words
                • Asthma Classifications of Nucala Patients
                • Current and Discontinued Prescriptions of Nucala
                • Regimen Additions and Changes When Prescribing Nucala
                • Additional Products Prescribed to Nucala Patients
                • Nucala’s Impact on Currently Available Products . . . in Their Own Words
              • Reasons for Not Yet Prescribing Nucala
                • Anticipated Nucala Use
                  • Anticipated Patients Initiated on Nucala Within the Next Month
                  • Physician Opinion
                  • Patient Candidates for Nucala . . . in Their Own Words
                • Nucala Performance on Key Attributes
                  • Level of Overall Satisfaction
                  • Level of Overall Satisfaction
                  • Experience with Nucala’s Managed Care Approval Process
                  • Nucala Insurance Coverage and Reimbursement Process. . . in Their Own Words
                  • Levels of Satisfaction with Specific Metrics
                  • Levels of Satisfaction with Specific Metrics
                  • Nucala Metrics. . . in Their Own Words
                  • Impact of Safety Concerns
                  • Impact of Safety Concerns
              • Effectiveness of Face-to-Face Detailing for Nucala
                • Nucala Sales Representative Frequency and Reach
                  • Last Visit by Nucala Representative
                  • Last Visit by Nucala Representative
                  • Sales Representative Details . . . in Their Own Words
                  • Materials Used by Representative During Visit
                  • Materials Provided by Sales Representatives
                  • Sales Representative Details . . . in Their Own Words
                • Satisfaction with Nucala Sales Representative
                  • Nucala Representative Performance Rating
                  • Nucala Representative Performance Rating
                  • Nucala Representative Detail . . . in Their Own Words
                • Nucala Message Recall
                  • Nucala Representative Discussion Topics (n = 11)
                  • Physician Opinion
                  • Nucala Representative Discussion Topics (n = 17)
                  • Physician Opinion
                  • Patient Type Suggested (n = 7^)
                  • Physician Opinion
                  • Patient Type Suggested (n = 15)
                  • Physician Opinion
              • Methodology
                • Significance Testing in This Study
                • Physician Demographics
                  • Years in Practice
                  • Regional Distribution of Pulmonologists
                  • Years in Practice
                  • Regional Distribution of Allergists
                  • Number of Asthma Patients
                  • Asthma Patient Severity
                  • Number of Asthma Patients
                  • Asthma Patient Severity
              • Appendix
                • Additional Primary Market Research
                  • Asthma Patients on Chronic Drug Treatment, by Severity
                  • Treatment Changes for Treatment-Naive Patients
                  • Patients on Each Step in the GINA Guidelines
                  • Requirements for Managed Care Approval of Nucala
                  • Nucala Copay Assistance Program . . . in Their Own Words
                  • Potential Use of Alternate Administration Routes
                  • Dosing and Administration of Nucala . . . in Their Own Words
                  • Products in Development
                  • Products in Development (n = 11^)
                  • Emerging Therapies . . . in Their Own Words
                  • Products in Development for Asthma
                  • Familiarity with Products in Development
                  • Familiarity with Products in Development
                  • Final Thoughts . . . in Their Own Words
                  • Report Abbreviations
                  • Objectives

            Author(s): Kristine Mackin, PhD

            Kristine Mackin, Ph.D., is an analyst on the immune and inflammatory disorders team at Decision Resources Group. She currently focuses on respiratory diseases, including asthma and COPD.

            She holds a doctorate in biochemistry from Brandeis University, where she studied the evolution of bacteriorhodopsin and the relationship between type I and type II rhodopsins. During her B.A. in Chemistry at Carleton College, she researched proinsulin processing. Prior to joining DRG, Dr. Mackin was involved with literature and market research for a new company pitch during an internship at Puretech Ventures in Boston, MA.


            Related Reports

            Asthma | Disease Landscape and Forecast | G7 | 2020

            The asthma market consists of many well-established therapies, including inhaled agents (e.g., GlaxoSmithKline’s Advair / Seretide, AstraZeneca’s Symbicort, Boehringer Ingelheim’s Spiriva), oral dr...

            View Details

            Asthma - Current Treatment - Detailed, Expanded Analysis (EU5)

            The asthma market in the EU5 is highly competitive. Ma...

            View Details

            Asthma - Landscape & Forecast - Disease Landscape & Forecast

            The asthma market consists of many well-established therapies, including inhaled agents (e.g., GlaxoSmithKline’s Advair / Seretide, AstraZeneca’s Symbicort, Boehringer Ingelheim’s...

            View Details